Healios Seals Deal with FDA for Phase 3 ARDS Study
Healios (TYO:4593) has reached an agreement with the Food and Drug Administration (FDA) on the design of the pivotal Phase 3 REVIVE-ARDS study for acute respiratory distress syndrome (ARDS) caused by pneumonia.
The study will measure the primary endpoint of Ventilator Free Days and include interim analyses at 300 and 400 patients, with a maximum enrollment of 550 patients, according to its filing on Monday.
Healios will also consult Japanese regulatory authorities for conditional approval, based on Phase 2 results and the initiation of the REVIVE-ARDS study.
Healios' shares gained nearly 4% recently.
Price (JPY): $221.00, Change: $+7.0, Percent Change: +3.27%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。